7-year heart trial finds Lp(a) drug doesn’t prevent heart attacks, but testing still matters
26 Articles
26 Articles
One in five people has an increased Lp(a) level – and thus a higher risk of heart attack and stroke. Pelacarsen should change this, but it fails in a large study.
They should lower the blood fat level Lp(a) and stop inflammation. However, the treatment did not work better than placebo. Researchers now have to question their basic assumptions.
Major heart drug trial falls short of expectations
CLEVELAND, Ohio — A drug that sharply lowered an inherited risk factor for heart disease did not reduce major cardiovascular events after nearly five years in a Cleveland Clinic-led clinical trial, according to results announced Saturday.
Novartis Experimental Heart Drug Fails Key Trial
A trial of an experimental Novartis drug designed to reduce a genetic risk factor for heart disease has failed to demonstrate a reduction in deaths, heart attacks or strokes, raising questions about the effectiveness of the treatment approach. The drug, pelacarsen, was developed to lower levels of lipoprotein(a), commonly known as Lp(a), a blood particle […]
Telemundo Area de la Bahía 48
Dr. Steven Nissen said the disappointing results took him for "extreme surprise."
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
